医药导报
醫藥導報
의약도보
HERALD OF MEDICINE
2015年
8期
987-992
,共6页
利拉鲁肽%超重%肥胖%系统评价%Meta分析%对照试验,随机
利拉魯肽%超重%肥胖%繫統評價%Meta分析%對照試驗,隨機
리랍로태%초중%비반%계통평개%Meta분석%대조시험,수궤
Liraglutide%Overweight%Obesity%Systematic review%Meta-analysis%Controlled trial,random
目的：采用Meta分析系统评价利拉鲁肽治疗超重和肥胖患者的有效性。方法采用计算机检索英文数据库( MEDLINE、EMbase、CENTRAL)和中文数据库(万方数据库、中国知网、维普数据库),查找利拉鲁肽治疗超重和肥胖患者的随机对照试验( RCT),检索时限截至2015年3月。由2位研究者根据纳入与排除标准独立筛选文献、提取资料并评价质量后,采用RevMan5.3.0版软件进行Meta分析。结果最终纳入12个RCT,其中英文文献11篇,中文文献1篇。结果显示在降低患者体质量方面,利拉鲁肽组优于安慰药组、胰岛素组、艾塞那肽组、格列美脲组,且差异均有统计学意义[RR=-0.91,95％CI(-1.01,-0.81),P<0.00001]、[RR=-2.88,95％CI(-3.37,-2.39),P<0.00001]、[RR=-1.12,95％CI(-1.32,-0.92),P<0.00001]、[RR=0.45,95％CI(-0.62,-0.27),P<0.00001]。利拉鲁肽在降低超重和肥胖患者糖化血红蛋白c、收缩压都有明显的效果。结论利拉鲁肽能有效控制超重和肥胖患者的体质量。其远期疗效有待开展更多高质量、大样本、长期随访的RCT加以验证。
目的：採用Meta分析繫統評價利拉魯肽治療超重和肥胖患者的有效性。方法採用計算機檢索英文數據庫( MEDLINE、EMbase、CENTRAL)和中文數據庫(萬方數據庫、中國知網、維普數據庫),查找利拉魯肽治療超重和肥胖患者的隨機對照試驗( RCT),檢索時限截至2015年3月。由2位研究者根據納入與排除標準獨立篩選文獻、提取資料併評價質量後,採用RevMan5.3.0版軟件進行Meta分析。結果最終納入12箇RCT,其中英文文獻11篇,中文文獻1篇。結果顯示在降低患者體質量方麵,利拉魯肽組優于安慰藥組、胰島素組、艾塞那肽組、格列美脲組,且差異均有統計學意義[RR=-0.91,95％CI(-1.01,-0.81),P<0.00001]、[RR=-2.88,95％CI(-3.37,-2.39),P<0.00001]、[RR=-1.12,95％CI(-1.32,-0.92),P<0.00001]、[RR=0.45,95％CI(-0.62,-0.27),P<0.00001]。利拉魯肽在降低超重和肥胖患者糖化血紅蛋白c、收縮壓都有明顯的效果。結論利拉魯肽能有效控製超重和肥胖患者的體質量。其遠期療效有待開展更多高質量、大樣本、長期隨訪的RCT加以驗證。
목적：채용Meta분석계통평개리랍로태치료초중화비반환자적유효성。방법채용계산궤검색영문수거고( MEDLINE、EMbase、CENTRAL)화중문수거고(만방수거고、중국지망、유보수거고),사조리랍로태치료초중화비반환자적수궤대조시험( RCT),검색시한절지2015년3월。유2위연구자근거납입여배제표준독립사선문헌、제취자료병평개질량후,채용RevMan5.3.0판연건진행Meta분석。결과최종납입12개RCT,기중영문문헌11편,중문문헌1편。결과현시재강저환자체질량방면,리랍로태조우우안위약조、이도소조、애새나태조、격렬미뇨조,차차이균유통계학의의[RR=-0.91,95％CI(-1.01,-0.81),P<0.00001]、[RR=-2.88,95％CI(-3.37,-2.39),P<0.00001]、[RR=-1.12,95％CI(-1.32,-0.92),P<0.00001]、[RR=0.45,95％CI(-0.62,-0.27),P<0.00001]。리랍로태재강저초중화비반환자당화혈홍단백c、수축압도유명현적효과。결론리랍로태능유효공제초중화비반환자적체질량。기원기료효유대개전경다고질량、대양본、장기수방적RCT가이험증。
Objective To evaluate the effectiveness and safety of liraglutide for obesity or overweight. Methods Random controlled trials of liraglutide for obesity or overweight were gathered from MEDLINE, EMbase, CENTRAL, CNKI, VIP and WanFang. We screened the retrieved studies according to the inclusion and exclusion criteria, evaluated the quality of included studies, and then performed meta-analyses with The Cochrane Collaboration's Revman 5. 3. 0 software. Results Twelve randomized controlled trials of liraglutide for obesity or overweight were included, in which 11 trials were written in English and one trial in Chinese. The results of meta-analyses showed that the body weight was significantly reduced in the liraglutide group than in placebo, insulin, exenatide and glimepiride groups [RR=-0. 91,95%CI(-1. 01,-0. 81),P<0. 000 01;RR=-2. 88,95%CI(-3. 37,-2. 39),P<0. 000 01; RR=-1. 12,95%CI(-1. 32,-0. 92),P<0. 000 01; RR=0. 45,95%CI(-0. 62,-0. 27),P<0. 000 01]. Moreover, liraglutide had significant effect in decreasing HbA1c and systolic blood pressure of patients with obesity or overweight. Conclusion Liraglutide is effective for controlling body weight of patients with obesity or overweight. But its long-term efficacy still needs to be confirmed by performing more RCTs with high quality, large sample and long term follow-up.
